According to Reuters, for every possible drug, Schrödinger typically evaluates thousands of molecules, basing his tests on physics, but he will now be able to do so with the help of machine learning systems.
By collaborating, the entire pharmaceutical industry – comprising more than 3,000 companies, from startups to multinationals – will be able to further accelerate the discovery of supercomputer-scale drugs.
“Computational drug discovery improves accuracy with Schrödinger’s advanced combination of simulation and machine learning,” said Kimberly Powell, Nvidia’s vice president of healthcare.
Not only AI, but also data centers
In addition to this partnership, Nvidia’s focus on developing new business is growing as it has introduced a new chipset: Grace.
Intel is the world’s largest manufacturer of core processors for data center servers, but has seen increasing competition from Arm-based chips. With its “Grace” server processor, Nvidia will be the largest chip company that has not yet challenged Intel in its key market.
Shares of Nvidia rose 2.6%, and Intel shares fell 4% when trading at noon after the news.
Arm’s technology powers the chips on most smartphones, but in recent years it has entered data centers, with companies such as Amazon and Ampere Computing designing chips for these companies.
Nvidia’s entry into the market could accelerate Arm’s forays into data centers. Nvidia chips have traditionally been used as “accelerators” alongside existing core processors from Intel, Advanced Micro Devices or others, downloading some of the computing work from them and speeding up the overall computing system.
By producing its own core processor, Nvidia takes over Intel and AMD for the first time. At GTC’s main address, Nvidia CEO Jensen Huang called the new server chip “the last piece of the puzzle” that will unite Nvidia’s graphics and network chips to form the “core block.” Of the modern data center ”.